Clinical trials
Gastroesophageal Adenocarcinoma clinical trials
Below are recruiting gastroesophageal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07481357RecruitingPhase 1
DA 3501 for advanced stomach or pancreatic cancer
This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.
Seongnam, BundangAges 19 years+ - NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Phoenix, ArizonaAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Study of spevatamig for advanced gastrointestinal cancers
This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.
Duarte, CaliforniaAges 18 years+ - NCT06649474Recruiting
Oxaliplatin side effects linked to HMGB1 blood levels
This study checks if a substance called HMGB1 in your blood is linked to nerve damage and liver side effects from the chemotherapy drug oxaliplatin. It is for people with a specific type of stomach or pancreas cancer that can be surgically removed.
Clermont-FerrandAges 18 years+ - NCT06245356RecruitingPhase 2
A safety trial of trifluridine/tipiracil for DPD-deficient patients
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
AmiensAges 18 years+ - NCT05733689RecruitingPhase 1
Testing new pre-surgery treatment for stomach and esophagus cancer
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
Orange, CaliforniaAges 18 years+ - NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06644352Recruiting
Comparing right vs. left chest surgery for junction cancer
This study compares two surgical approaches (right side of the chest vs. left side of the chest) for removing a certain type of cancer at the gastroesophageal junction. It aims to find which approach leads to better outcomes.
BeijingAges 18–80 - NCT04219137Recruiting
MOCHA study of blood and biopsy features in stomach tumors
This study looks at the “molecular” features (biologic characteristics) of gastroesophageal cancer from tissue samples. It may help doctors better understand which cancers are best matched to treatment plans and future therapies.
Toronto, OntarioAges 18 years+ - NCT07790809Recruiting
Robotic surgery for stomach and esophagus junction cancer
This study tests a new robotic surgery system for a specific type of stomach-adjacent cancer. The goal is to see if the robotic approach is safe and effective in removing the tumor.
Changchun, JilinAges 18–80 - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Duarte, CaliforniaAges 18 years+ - NCT07102901RecruitingPhase 2
Study of SHR2554 with other therapies for gastric or junction cancer
This trial tests a new drug, SHR2554, combined with other anticancer treatments for advanced stomach or gastroesophageal junction cancer. It aims to see if the combination is safe and effective. You may qualify if you have measurable disease and are generally in good health.
Harbin, HeilongjiangAges 18–75 - NCT06829797RecruitingPhase 2
Iparomlimab and chemotherapy vs chemotherapy alone for stomach cancer
This trial tests whether adding an immunotherapy drug (Iparomlimab and Tuvonralimab, combined as QL1706) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced stomach or gastroesophageal junction cancer that can be surgically removed.
Jinan, ShandongAges 18–75 - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT07801508RecruitingPhase 1
Trial of a new imaging agent for people with advanced solid tumors
This trial tests a radioactive imaging agent that may help doctors see tumors more clearly using a special scan. It is designed for adults with certain breast, lung, or stomach cancers that have spread.
Darlinghurst, New South WalesAges 18 years+ - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT06529822RecruitingPhase 1
Personalized cancer vaccine for solid tumors with residual disease
This trial tests a personalized cancer vaccine designed to help your immune system fight any remaining cancer cells after surgery. It is for people with certain solid tumors—like bladder, stomach, melanoma, or lung cancer—that show signs of disease through a blood test.
Orlando, FloridaAges 18 years+ - NCT07362186RecruitingPhase 3
LM-108 with Toripalimab vs Paclitaxel for advanced stomach cancer
This trial tests a new combination of two immunotherapy drugs (LM-108 and Toripalimab) against a standard chemotherapy drug (Paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CCR8. It may be an option if you have already tried a first-line therapy and your cancer has progressed or you had side effects from chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06846996Recruiting
Study of trastuzumab deruxtecan for advanced stomach cancer
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
BeijingAges 18 years+ - NCT07556640RecruitingPhase 2
Drug combination for stomach cancer with abdominal spread
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
Shanghai, Huangpu DistrictAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Anchorage, AlaskaAges 18 years+ - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT06560528RecruitingPhase 2
Drug combo before & after surgery for HER2+ stomach cancer
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastroesophageal adenocarcinoma?
- Yes. Clin2 currently lists 161 recruiting gastroesophageal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastroesophageal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastroesophageal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastroesophageal Junction Adenocarcinoma
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Locally Advanced Gastroesophageal Junction Adenocarcinoma
- Unresectable Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.